top of page




Professor Jin Ling TANG joined the Department of Community and Family Medicine of the Chinese University of Hong Kong in 1995. He qualified as a public health doctor in Peking University Medical School (formerly Beijing Medical University) and was later awarded, by the Chinese Ministry of Education, the Sino-British Friendship Scholarship for reading for a PhD in the United Kingdom. He obtained his Master of Science degree in epidemiology in London School of Hygiene and Tropical Medicine and PhD in the UCL (University of London), and received post-doctoral training in the University of Oxford. Professor Tang was awarded in 2002 Cheung Kong Scholars Professor of Peking University by the Ministry of Education and Li Ka Shing Foundation.

Professor Tang is a trained epidemiologist and has a major interest in evidence-based healthcare, traditional Chinese medicine, systematic reviews, appraisal of medical evidence, and prevention of cardiovascular diseases. He headed the Hong Kong Cochrane Branch of the Cochrane Collaboration between 2002 and 2019 and is the Chairman of the Asia Pacific Network for Evidence-Based Medicine. He was Chairman of Peking University National 211 Committee for Evidence-Based Medicine and Clinical Research and heads Peking University Centre for Evidence-Based Medicine and Clinical Research. Professor Tang was also former Vice President of Asia Pacific Consortium for Public Health and is guest professor of Peking University, Fudan University, Zhejiang University, Peking Union Medical School, and China Academy of Chinese Medical Sciences.

Professor Tang is currently clinical research editor of British Medical Journal and serves as an editorial board member of medical journals including British Medical Journal-Chinese Edition and Journal of Evidence-Based Medicine. He proposed the efficacy driven approach to research and development in traditional Chinese medicine to the Legislative Council of the Hong Kong Government and was invited to speak on the topic at the World Economic Forum 2001 China Business Summit. He co-authored Evidence-Based Decision Making in Healthcare with Sir Muir Gray of the University of Oxford and was the co-editor of the Chinese version of the BMJ Clinical Evidence. He has supervised over 100 PhD, MPH and MSc students.


  • Randomized controlled trials

  • Clinical research methods

  • Evidence-based medicine

  • Over-diagnosis

  • Clinical evaluation of traditional Chinese medicine

  • Primary prevention of cardiovascular disease


  1. Lei Luo, Dan Liu, Xinlong Liao, Xingfen Yang, Zhigang Han, Jinling Tang, Yu Ma, Chen Mao. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China: A Prospective Cohort Study. Annals of Internal Meicine. 13 August 2010,

  2. Yi Xu, Xufang Li, Bing Zhu, Huimin Xia, Jinling Tang, Kang Zhang & Sitang Gong Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020(26): 502–505.

  3. Qi Feng, Aoshuang Zhou, Huachun Zou, Suzanne Ingle, Margaret T May, Weiping Cai, Chien-Yu Cheng, Zuyao Yang, Jinling Tang. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomized controlled trials. BMJ 2019; 366 doi: (IF=30.2)

  4. Allan Hackshaw, Joan K Morris, Sadie Boniface, Jin-Ling Tang. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. British Medical Journal 2018;360:j3984 | doi: 10.1136/bmj.j3984 IF:30.2)

  5. Zu-Yao Yang, Hong Fan, Jin-Ling Tang. Considerations Concerning Disease Redefinition. JAMA Internal Medicine 2017;177(12):1872-1873. IF:16.4)

  6. Di MY, Liu H, Yang ZY, Bonis PAL, Tang JL, Lau J. Prediction Models of Mortality in Acute Pancreatitis in Adults: A Systematic Review. Ann Intern Med, 2016, 165(7):482-490. (IF: 19.4)

  7. Wong KS, Wang Y, Leng X, Mao C, Tang JL, Bath PM, Markus HS, Gorelick PB, Liu L, Lin W, Wang Y. Response to letter regarding article, "early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis". Circulation, 2014, 130(8):e74. (IF: 18.9)

  8. Wong KS, Wang Y, Leng X, Mao C, Tang JL, Bath PM, Markus HS, Gorelick PB, Liu L, Lin W, Wang Y. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation, 2013, 128(15): 1656-1666. (IF: 18.9)

  9. Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, Qin X, Ren Z, Ding H, Chen Q, Mao C, Tang JL. Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis. European Urology, 2013, 63(5):902-912. (IF: 13.938)

  10. Yuan JQ, Mao C, Tang JL. Risk factors for non-communicable diseases in prison populations (correspondence). Lancet, 2012, 380(9849):1227. (IF: 53.2)

Last Updated: 8 September 2020

bottom of page